209 related articles for article (PubMed ID: 28373217)
1. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.
Garcia-Neuer M; Marmarelis ME; Jangi SR; Luke JJ; Ibrahim N; Davis M; Weinberg J; Donahue H; Bailey N; Hodi FS; Buchbinder EL; Ott PA
Cancer Immunol Res; 2017 Apr; 5(4):286-291. PubMed ID: 28373217
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
3. Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.
Herlihy JD; Beasley S; Simmelink A; Maddukuri V; Amin A; Kamionek M; Jacobs C; Bossi K; Scobey M
South Med J; 2019 Mar; 112(3):154-158. PubMed ID: 30830228
[TBL] [Abstract][Full Text] [Related]
4. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
[No Abstract] [Full Text] [Related]
5. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
Lesage C; Longvert C; Prey S; Maanaoui S; Dréno B; Machet L; Zehou O; Kramkimel N; Jeudy G; Skowron F; Aubin F; Visseaux L; Mansard S; Dereure O; Lesage FX; Guillot B;
J Immunother; 2019 Jun; 42(5):175-179. PubMed ID: 31090656
[TBL] [Abstract][Full Text] [Related]
7. Acute visual loss after ipilimumab treatment for metastatic melanoma.
Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
[TBL] [Abstract][Full Text] [Related]
8. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic findings of ipilimumab-induced colitis.
Satoh T; Ohno K; Kurokami T
Dig Endosc; 2017 May; 29(3):388-389. PubMed ID: 28128877
[No Abstract] [Full Text] [Related]
10. A Life-Threatening Cause of Colitis.
Jaswani TS; Grider DJ; Bern MJ
Gastroenterology; 2018 Jan; 154(1):35-36. PubMed ID: 28918915
[No Abstract] [Full Text] [Related]
11. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
[TBL] [Abstract][Full Text] [Related]
12. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
[No Abstract] [Full Text] [Related]
13. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
[TBL] [Abstract][Full Text] [Related]
14. Challenging Cases: Management of Immune-Related Toxicity.
Weber JS
Am Soc Clin Oncol Educ Book; 2018 May; 38():179-183. PubMed ID: 30231403
[TBL] [Abstract][Full Text] [Related]
15. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
[TBL] [Abstract][Full Text] [Related]
16. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
[TBL] [Abstract][Full Text] [Related]
18. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
Jørgensen LB; Yderstræde K
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918779
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
20. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]